SCHEDULE: Vanguard Discloses 5.01% Stake in Trevi Therapeutics

The Vanguard Group reported a 5.01% beneficial ownership stake in Trevi Therapeutics Inc. common stock as of December 31, 2025.

Summary

• The Vanguard Group beneficially owns 6,434,655 shares of Trevi Therapeutics Inc. Common Stock.
• This ownership represents 5.01% of the class of securities.
• The Vanguard Group holds shared voting power over 833,386 shares and shared dispositive power over 6,434,655 shares.
• An internal realignment occurred at The Vanguard Group, Inc. on January 12, 2026, after which it no longer performs portfolio management services or administers proxy voting.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. are expected to report beneficial ownership separately (on a disaggregated basis).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive filing, as it confirms a significant institutional stake by a major passive investor, which can provide some stability, but offers no new operational or financial insights into Trevi Therapeutics.

Positives

• A major institutional investor, The Vanguard Group, holds a significant 5.01% stake in Trevi Therapeutics Inc., indicating institutional interest and potentially providing market stability.

Risks

• The filing itself does not detail specific risks related to Trevi Therapeutics Inc.'s operations or financial health.

Future Outlook

NA (This Schedule 13G filing reports historical ownership data and does not provide forward-looking statements or guidance for Trevi Therapeutics Inc.)

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting."
• "The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."

Industry Context

StockSavvy.ai notes that institutional filings like Schedule 13G provide transparency into significant ownership stakes, which can influence market perception. Vanguard's passive investment strategy often means their holdings reflect broad market exposure rather than specific bullish bets on individual companies, though a 5% stake is a notable threshold.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional ownership stake, which may contribute to market confidence and liquidity.
• Management: Awareness of a large, passive institutional holder may influence strategic considerations, though Vanguard's role is typically non-interventional.

Next Steps

• Certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. following the internal realignment.

Key Dates

Recommendation

The filing indicates a significant passive institutional ownership by The Vanguard Group, which typically reflects broad market exposure rather than a specific investment thesis on Trevi Therapeutics. While it signals institutional presence, it does not provide new operational or financial data to warrant a change in investment strategy, thus a 'hold' is appropriate for existing investors pending further fundamental analysis.

Keywords

Trevi Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing